Responsiveness of Adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 863-870

  Von Minckwitz, Gunter ^a   Darb Esfahani, Silvia ^b   Loibl, Sibylle ^a   Huober, Jens ^c   Tesch, Hans ^d   Solbach, Christine ^e   Holms, Frank ^f   Eidtmann, Holger ^g   Dietrich, Klaus ^h   Just, Marianne ⁱ   Clemens, Michael R ^j   Hanusch, Claus ^k   Schrader, Iris ^l   Henschen, Stephan ^m   Hoffmann, Gerald ⁿ   Tiemann, Katharina ^f   Diebold, Kurt ^m   Untch, Michael ^o   Denkert, Carsten ^b  

^a C/o GBG Forschungs GmbH ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d Bethanien Krankenhaus Frankfurt   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f St Barbara Kliniken Heessen   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ Onkologische Schwerpunktpraxis   (Germany)

^j Hospital Mutterhaus of the Borromäerinnen   (Germany)

^k Rotkreuzklinikum   (Germany)

^l Henriettenstiftung   (Germany)

^m Johanniter Krankenhaus   (Germany)

ⁿ ST JOSEFS HOSPITAL   (Germany)

^o HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

Breast cancer; Ductal carcinoma in situ; HER2; Neoadjuvant trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; HORMONE RECEPTOR; KI 67 ANTIGEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; EARLY CANCER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR BIOPSY; UPREGULATION; ADJUVANT THERAPY; AGED; BREAST TUMOR; FEMALE; METABOLISM; MIDDLE AGED; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASMS, MULTIPLE PRIMARY; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 84865182133     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1621-0     Document Type: Article

References (20)

1. Gao Y, Niu Y, Wang X, Wei L, Lu S (2009) Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med 87:145-152
2. Steinman S, Wang J, Bourne P, Yang Q, Tang P (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37:127-134
3. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, Hofler H, Werner M (2000) Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 85:82-86
4. Alexe G, Dalgin GS, Ganesan S, Delisi C, Bhanot G (2007) Analysis of breast cancer progression using principal component analysis and clustering. J Biosci 32:1027-1039
5. Iakovlev V, Arneson N, Wong V, Wang C, Leung S, Iokovleva G, Warren K, Pintilie M, Done S (2008) Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 14:4446-4454
6. Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102(9):1391-1396
7. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Löhrs U (2003) EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 79(2):187-198
8. Stackievicz R, Paran H, Bernheim J, Shapira M, Weisenberg N, Kaufman T, Klein E, Gutman M (2010) Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J 12(5):290-295
9. Kühn T (2010) Ductal carcinoma in situ: clinical perspective. Breast Care 5:227-232
10. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M (2010) Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28(12):2015-2023
11. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28(12):2024-2031
12. Sinn HP, Schmid H, Junkermann H (1994) Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54:552-558
13. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P (2010) Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 36(Suppl 3):S62-S66
14. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF (2011) Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117:39-47
15. von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M for the GBG and AGO-B study groups (2011) Correlation of various pathological complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes. Results from the German neoadjuvant meta-analysis. J Clin Oncol 29(suppl):2011. 1028. ASCO 2011
16. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta K, von Minckwitz G, Loibl S (2011) Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer-results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol (in press)
17. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384
18. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kuehn T, Nekljudova V, von Minckwitz G (2010) Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane- based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). SABCS, San Antonio, Dec. 2010. S3-1
19. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M, on Behalf of the NeoALTTO Study Team. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. SABCS, San Antonio, Dec. 2010. S3-3
20. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A, Semiglazov V, Szado T, Ross G. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). SABCS, San Antonio, Dec. 2010. S3-2